Form 4: ResMed CEO Michael Farrell Executes Stock Options and Sells Shares
SEC Form 4
ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares on March 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 7, 2025, Michael J. Farrell, the CEO of ResMed Inc., executed options to acquire 8,009 shares of ResMed common stock at a price of $101.64 per share.
- Simultaneously, Farrell sold 8,009 shares of ResMed common stock at a weighted average price of $229.2037, with individual sales prices ranging from $223.64 to $232.39.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024.
- Following these transactions, Farrell directly owns 455,472 shares of ResMed common stock.
- Farrell also indirectly owns 2,090 shares through the Lisette and Michael Farrell Foundation and the Lisette and Michael Farrell Family Trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports transactions by an executive under a pre-existing plan. There is no indication of positive or negative implications for the company's performance.
Positives
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan can alleviate these concerns.
Future Outlook
The document does not contain any specific forward-looking statements or guidance from the company.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are generally benchmarked against peer companies within the medical device industry.
- Companies like Philips, Medtronic, and Stryker also utilize stock options as part of their executive compensation packages.
- The use of Rule 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 11/11/2019 | Date options first become exercisable. |
| 10/31/2024 | Date of adoption of Rule 10b5-1 plan. |
| 03/07/2025 | Date of stock option exercise and sale. |
| 11/14/2025 | Expiration date of the ResMed Common Stock Options. |
| 03/10/2025 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.